ЭКСТРАКОРПОРАЛЬНЫЕ МЕТОДЫ ДЕТОКСИКАЦИИ У БОЛЬНЫХ С ПЕЧЕНОЧНОЙ НЕДОСТАТОЧНОСТЬЮ: ТРИДЦАТЬ ЛЕТ СПУСТЯ
Обзорная статья
Дата публикации: июня 7, 2024
Ключевые слова
печеночная недостаточность
детоксикация
детоксикация
Как цитировать
Кутепов Д. Е., Пасечник И. Н., Бояринцев В. В. ЭКСТРАКОРПОРАЛЬНЫЕ МЕТОДЫ ДЕТОКСИКАЦИИ У БОЛЬНЫХ С ПЕЧЕНОЧНОЙ НЕДОСТАТОЧНОСТЬЮ: ТРИДЦАТЬ ЛЕТ СПУСТЯ // Кремлевская медицина. Клинический вестник. 2024. Т. № 2. С. 110-116.
Аннотация
Экстракорпоральные методы детоксикации у больных с печеночной недостаточностью применяются с целью протезирования функции печени в качестве «моста» до возможного спонтанного восстановления функции печени или до трансплантации печени. За последние 30 лет экстракорпоральные методы детоксикации прошли долгий путь от гемодиализа и плазмафереза до систем «искусственная печень». В обзоре представлены результаты применения данных систем, описаны их возможности по лечению больных с печеночной недостаточностью.Литература
1. García Martínez J.J. et al. Artificial liver support systems: what is new over the last decade? // Annals of intensive care. – 2018. – V. 8. – P. 1–14. DOI: 10.1186/s13613-018-0453-z.
2. Tandon R. et al. Artificial liver support systems // Journal of Gastroenterology and Hepatology. – 2021. – V. 36. – No 5. – P. 1164–1179. DOI: 10.1111/jgh.15255.
3. Garcia-Martinez R. et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications // Hepatology. – 2013. – V. 58. – No 5. – P. 1836–1846. DOI: 10.1002/hep.26338.
4. Кутепов Д.Е. и др. Возможности экстракорпоральных методов лечения печеночной недостаточности // Хирургия. Журнал им. Н.И. Пирогова. – 2014. – № 2. – С. 55–58. [Kutepov D.E. et al. Possibilities of extracorporeal methods of tre atmentof liver failure // Surgery. Magazine named N.I. Pirogov. – 2014. – No 2. – P. 55–58. In Russian].
5. Бояринцев В.В. и др. Хроническая печеночная недостаточность. – Санкт-Петербург: Фолиант, 2017. – С. 188. [Boyarintsev V.V. et al. Chronic liver failure. – Saint-Petersburg: Foliant, 2017. – P. 188. In Russian].
6. Dominik A. et al. Similarities, differences, and potential synergies in the mechanism of action of albumin dialysis using the MARS albumin dialysis device and the CytoSorb hemoperfusion device in the treatment of liver failure // Blood Purification. – 2021. – V. 50. – No 1. – P. 119–128. DOI: 10.1159/000508810.
7. Adham M. Methods of extracorporeal liver support for treatment of liver cell failure // Zeitschrift für Gastroenterologie. – 2001. – V. 39. – No S2. – P. 1–5. DOI: 10.1055/s-2001-919020.
8. Yokoi T. et al. Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure // Transfusion and Apheresis Science. – 2009. – V. 40. – No 1. – P. 61–70. DOI: 10.1016/j.transci.2008.11.006.
9. Larsen F.S. et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial // Journal of Hepatology. – 2016. – V. 64. – No 1. – P. 69–78. DOI: 10.1016/j.jhep.2015.08.018.
10. Maiwall R. et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: a randomized controlled trial // Clinical Gastroenterology and Hepatology. – 2022. – V. 20. – No 4. – P. e831–e854. DOI: 10.1016/j.cgh.2021.01.036.
11. Tan E. X.X. et al. Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review // World journal of gastroenterology. – 2020. – V. 26. – No 2. – P. 219. DOI: 10.3748/wjg.v26.i2.219.
12. Kondrup J. et al. High volume plasma exchange in fulminant hepatic failure // The International Journal of Artificial Organs. – 1992. – V. 15. – No 11. – P. 669–676.
13. Wu C. et al. Efficacy and economic evaluation of nonbiological artificial liver therapy in acute-on-chronic hepatitis B liver failure // Journal of Clinical and Translational Hepatology. – 2023. – V. 11. – No 2. – P. 433. DOI: 10.14218/JCTH.2022.00106.
14. Ocak I.A 15-year retrospective study of supportive extracorporeal therapies including plasma exchange and continuous veno-venous hemodiafiltration of 114 adults with acute liver failure awaiting liver transplantation // Annals of Transplantation. – 2023. – V. 28. – P. e939745-1. DOI: 10.12659/AOT.939745.
15. Mitzner S.R. et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial // Liver transplantation. – 2000. – V. 6. – No 3. – P. 277–286. DOI: 10.1002/lt.500060326.
16. Kantola T. et al. Survival predictors in patients treated with a molecular adsorbent recirculating system // World Journal of Gastroenterology: WJG. – 2009. – V. 15. – No 24. – P. 3015. DOI: 10.3748/wjg.15.3015.
17. Gerth H.U. et al. Molecular adsorbent recirculating system can reduce short-term mortality among patients with acute-on-chronic liver failure – a retrospective analysis // Critical care medicine. – 2017. – V. 45. – No 10. – P. 1616. DOI: 10.1097/CCM.0000000000002562.
18. Бокерия Л.А. и др. Альбуминовый диализ в комплексной интенсивной терапии больных после кардиохирургических операций. Первый собственный опыт //Анестезиология и реаниматология. – 2005. – № 2. – С. 78–83. [Bokeria L.A. et al. Albumin dialysis in complex intensive care of patients after cardiac surgery. First own experience // Anesthesiology and Resuscitation. – 2005. – No 2. – P. 78–83. In Russian].
19. Еремеева Л.Ф. и др. Система гемостаза при МАРС-терапии и сорбции плазмы у пациентов с печеночно-клеточной недостаточностью // Общая реаниматология. – 2010. – Т. 6. – № 5. – С. 35. [Eremeeva L.F. et al. Hemostasis system in MARS therapy and plasma sorption in patients with hepatic cell insufficiency // General Resuscitation. – 2010. – V. 6. – No 5. – P. 35. In Russian]. DOI: 10.15360/1813-9779-2010-5-35.
20. Кутепов Д.Е. и др. Роль и место альбуминового диализа в лечении больных с печеночной недостаточностью // Анестезиология и реаниматология. – 2010. – № 2. – С. 53–58. [Kutepov D.E. et al. The role and place of albumin dialysis in the treatment of patients with liver failure // Anesthesiology and Resuscitation. – 2010. – No 2. – P. 53–58. In Russia].
21. Хорошилов С.Е. и др. Острая (молниеносная) и острая/хроническая печеночная недостаточность: возможности коррекции альбуминовым диализом на аппарате MARS // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2007. – Т. 17. – № 2. – С. 57–62. [Khoroshilov S.E. et al. Acute (lightning-fast) and acute/chronic liver failure: possibilities of correction by albumin dialysis on the MARS device // Russian Journal of Gastroenterology, Hepatology, Coloproctology. – 2007. – V. 17. – № 2. – P. 57–62. In Russian].
22. Кутепов Д.Е. и др. Повторное применение молекулярной рециркулирующей адсорбирующей системы у больных с декомпенсацией цирроза печени // Медицинский альманах. – 2013. – № 1 (25). – С. 52–54. [Kutepov D.E. et al. Repeated application of the molecular recirculating adsorbing system in patients with decompensation of liver cirrhosis // Medical Almanac. – 2013. – No 1 (25). – P. 52–54. In Russian].
23. Kribben A. et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure // Gastroenterology. – 2012. – V. 142. – No 4. – P. 782–789e3. DOI: 10.1053/j.gastro.2011.12.056.
24. Churchwell M.D. et al. Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis // Nephrology Dialysis Transplantation. – 2009. – V. 24. – No 1. – P. 231–238. DOI: 10.1093/ndt/gfn467.
25. Benyoub K. et al. Amounts of bile acids and bilirubin removed during single‐pass albumin dialysis in patients with liver failure // Therapeutic apheresis and dialysis. – 2011. – V. 15. – No 5. – P. 504–506. DOI: 10.1111/j. 1744-9987.2011.00980.х.
26. Schmuck R.B. et al. Single pass albumin dialysis: a dose‐finding study to define optimal albumin concentration and dialysate flow // Artificial Organs. – 2017. – V. 41. – No 2. – P. 153–161. DOI: 10.1111/aor.12736.
27. Ho D.W.Y. et al. Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model // Gut. – 2002. – V. 50. – No 6. – P. 869–876. DOI: 10.1136/gut.50.6.869.
28. Соколов А.А. и др. Возможности селективной плазмофильтрации при заболеваниях печени // Эфферентная терапия. – 2013. – Т. 19. – № 1. – С. 103–104. [Sokolov A.A. et al. Possibilities of selective plasma filtration in liver diseases // Efferent Therapy. – 2013. – V. 19. – No 1. – P. 103–104. In Russian].
29. Фомин А.М. Оценка эффективности селективной плазмофильтрации при механической желтухе // Евразийский союз ученых. – 2016. – № 7–1 (28). – С. 43–44. [Fomin A.M. Evaluation of the effectiveness of selective plasma filtration in mechanical jaundice // Eurasian Union of Scientists. – 2016. – No 7–1 (28). – P. 43–44. In Russian].
30. Соколов А.А. и др. Сравнение селективного плазмообмена и плазморадиофильтрации системами MARS и Prometheus при лечении печеночной недостаточности // Вестник анестезиологии и реаниматологии. – 2020. – Т. 17. – № 3. – С. 39–52. [Sokolov A.A. et al. Comparison of selective plasma exchange and plasma radiofiltration by MARS and Prometheus systems in the treatment of liver failure // Bulletin of Anesthesiology and Resuscitation. – 2020. – V. 17. – No 3. – P. 39–52. In Russian]. DOI: 10.21292/2078-5658-2020-17-3-39-52.
31. Nakae H. et al. Multicenter study of plasma diafiltration in patients with acute liver failure // Therapeutic Apheresis and Dialysis. – 2010. – V. 14. – No 5. – P. 444–450. DOI: 10.1111/j.1744-9987.2010.00864.x.
32. Zhang Y. et al. Efficacy and safety of plasma diafiltration: Review of case reports and case series // Therapeutic Apheresis and Dialysis. – 2023. – V. 27. – No 1. – P. 3–11. DOI: 10.1111/1744-9987.13859.
33. Donati G. et al. Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study) // Journal of Nephrology. – 2021. – V. 34. – P. 77–88. DOI: 10.1007/s40620-020-00799-w.
34. Ocskay K. et al. Hemoadsorption in ‘liver indication’ – analysis of 109 patients’ data from the cytosorb international registry // Journal of Clinical Medicine. – 2021. – V. 10. – No 21. – P. 5182. DOI: 10.3390/jcm10215182.
35. Senf R. et al. Bilirubin-adsorption in 23 critically ill patients with liver failure // The International Journal of Artificial Organs. – 2004. – V. 27. – No 8. – P. 717–722. DOI: 10.1177/039139880402700810.
36. Adani G.L. et al. Selective bilirubin removal by plasma treatment with Plasorba BR-350 for early cholestatic graft dysfunction // Transplantation Proceedings. – Elsevier, 2007. – V. 39. – No 6. – P. 1904–1906.
37. Фомин А.М. и др. Оценка эффективности плазмосорбции (Liver Support) при печеночной недостаточности у больных с механической желтухой // Альманах клинической медицины. – 2015. – № 40. – С. 101–108. [Fomin A.M. et al. Evaluation of the effectiveness of plasmosorption (Liver Support) in hepatic insufficiency in patients with mechanical jaundice. // Almanac of Clinical Medicine. – 2015. – No 40. – P. 101–108. In Russian].
38. Huber W. et al. First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis // BMC Gastroenterology. – 2017. – V. 17. – P. 1–11. DOI: 10.1186/s12876-017-0569-x.
39. Fuhrmann V. et al. Registry on extracorporeal multiple organ support with the advanced organ support (ADVOS) system: 2-year interim analysis // Medicine. – 2021. – V. 100. – No 7. DOI: 10.1097/MD.0000000000024653.
40. Hogen R. et al. The Evolving Role of Extra-corporeal Membrane Oxygenation in Liver Transplantation // Current opinion in organ transplantation. – 2021. – V. 26. – No 3. – P. 333. DOI: 10.1097/MOT.0000000000000874.
41. Wu W.K. et al. Extracorporeal membrane oxygenation in patients with hepatopulmonary syndrome undergoing liver transplantation: a systematic review of the literature // Transplantation Reviews. – 2022. – V. 36. – No 2. – P. 100693. DOI: 10.1016/j.trre.2022.100693.
42. Reid T.D. et al. The role of extracorporeal membrane oxygenation in adult liver transplant patients: A qualitative systematic review of literature // Artificial Organs. – 2022. – V. 46. – No 4. – P. 578–596. DOI: 10.1111/aor.14120.
2. Tandon R. et al. Artificial liver support systems // Journal of Gastroenterology and Hepatology. – 2021. – V. 36. – No 5. – P. 1164–1179. DOI: 10.1111/jgh.15255.
3. Garcia-Martinez R. et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications // Hepatology. – 2013. – V. 58. – No 5. – P. 1836–1846. DOI: 10.1002/hep.26338.
4. Кутепов Д.Е. и др. Возможности экстракорпоральных методов лечения печеночной недостаточности // Хирургия. Журнал им. Н.И. Пирогова. – 2014. – № 2. – С. 55–58. [Kutepov D.E. et al. Possibilities of extracorporeal methods of tre atmentof liver failure // Surgery. Magazine named N.I. Pirogov. – 2014. – No 2. – P. 55–58. In Russian].
5. Бояринцев В.В. и др. Хроническая печеночная недостаточность. – Санкт-Петербург: Фолиант, 2017. – С. 188. [Boyarintsev V.V. et al. Chronic liver failure. – Saint-Petersburg: Foliant, 2017. – P. 188. In Russian].
6. Dominik A. et al. Similarities, differences, and potential synergies in the mechanism of action of albumin dialysis using the MARS albumin dialysis device and the CytoSorb hemoperfusion device in the treatment of liver failure // Blood Purification. – 2021. – V. 50. – No 1. – P. 119–128. DOI: 10.1159/000508810.
7. Adham M. Methods of extracorporeal liver support for treatment of liver cell failure // Zeitschrift für Gastroenterologie. – 2001. – V. 39. – No S2. – P. 1–5. DOI: 10.1055/s-2001-919020.
8. Yokoi T. et al. Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure // Transfusion and Apheresis Science. – 2009. – V. 40. – No 1. – P. 61–70. DOI: 10.1016/j.transci.2008.11.006.
9. Larsen F.S. et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial // Journal of Hepatology. – 2016. – V. 64. – No 1. – P. 69–78. DOI: 10.1016/j.jhep.2015.08.018.
10. Maiwall R. et al. Standard-volume plasma exchange improves outcomes in patients with acute liver failure: a randomized controlled trial // Clinical Gastroenterology and Hepatology. – 2022. – V. 20. – No 4. – P. e831–e854. DOI: 10.1016/j.cgh.2021.01.036.
11. Tan E. X.X. et al. Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review // World journal of gastroenterology. – 2020. – V. 26. – No 2. – P. 219. DOI: 10.3748/wjg.v26.i2.219.
12. Kondrup J. et al. High volume plasma exchange in fulminant hepatic failure // The International Journal of Artificial Organs. – 1992. – V. 15. – No 11. – P. 669–676.
13. Wu C. et al. Efficacy and economic evaluation of nonbiological artificial liver therapy in acute-on-chronic hepatitis B liver failure // Journal of Clinical and Translational Hepatology. – 2023. – V. 11. – No 2. – P. 433. DOI: 10.14218/JCTH.2022.00106.
14. Ocak I.A 15-year retrospective study of supportive extracorporeal therapies including plasma exchange and continuous veno-venous hemodiafiltration of 114 adults with acute liver failure awaiting liver transplantation // Annals of Transplantation. – 2023. – V. 28. – P. e939745-1. DOI: 10.12659/AOT.939745.
15. Mitzner S.R. et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial // Liver transplantation. – 2000. – V. 6. – No 3. – P. 277–286. DOI: 10.1002/lt.500060326.
16. Kantola T. et al. Survival predictors in patients treated with a molecular adsorbent recirculating system // World Journal of Gastroenterology: WJG. – 2009. – V. 15. – No 24. – P. 3015. DOI: 10.3748/wjg.15.3015.
17. Gerth H.U. et al. Molecular adsorbent recirculating system can reduce short-term mortality among patients with acute-on-chronic liver failure – a retrospective analysis // Critical care medicine. – 2017. – V. 45. – No 10. – P. 1616. DOI: 10.1097/CCM.0000000000002562.
18. Бокерия Л.А. и др. Альбуминовый диализ в комплексной интенсивной терапии больных после кардиохирургических операций. Первый собственный опыт //Анестезиология и реаниматология. – 2005. – № 2. – С. 78–83. [Bokeria L.A. et al. Albumin dialysis in complex intensive care of patients after cardiac surgery. First own experience // Anesthesiology and Resuscitation. – 2005. – No 2. – P. 78–83. In Russian].
19. Еремеева Л.Ф. и др. Система гемостаза при МАРС-терапии и сорбции плазмы у пациентов с печеночно-клеточной недостаточностью // Общая реаниматология. – 2010. – Т. 6. – № 5. – С. 35. [Eremeeva L.F. et al. Hemostasis system in MARS therapy and plasma sorption in patients with hepatic cell insufficiency // General Resuscitation. – 2010. – V. 6. – No 5. – P. 35. In Russian]. DOI: 10.15360/1813-9779-2010-5-35.
20. Кутепов Д.Е. и др. Роль и место альбуминового диализа в лечении больных с печеночной недостаточностью // Анестезиология и реаниматология. – 2010. – № 2. – С. 53–58. [Kutepov D.E. et al. The role and place of albumin dialysis in the treatment of patients with liver failure // Anesthesiology and Resuscitation. – 2010. – No 2. – P. 53–58. In Russia].
21. Хорошилов С.Е. и др. Острая (молниеносная) и острая/хроническая печеночная недостаточность: возможности коррекции альбуминовым диализом на аппарате MARS // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2007. – Т. 17. – № 2. – С. 57–62. [Khoroshilov S.E. et al. Acute (lightning-fast) and acute/chronic liver failure: possibilities of correction by albumin dialysis on the MARS device // Russian Journal of Gastroenterology, Hepatology, Coloproctology. – 2007. – V. 17. – № 2. – P. 57–62. In Russian].
22. Кутепов Д.Е. и др. Повторное применение молекулярной рециркулирующей адсорбирующей системы у больных с декомпенсацией цирроза печени // Медицинский альманах. – 2013. – № 1 (25). – С. 52–54. [Kutepov D.E. et al. Repeated application of the molecular recirculating adsorbing system in patients with decompensation of liver cirrhosis // Medical Almanac. – 2013. – No 1 (25). – P. 52–54. In Russian].
23. Kribben A. et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure // Gastroenterology. – 2012. – V. 142. – No 4. – P. 782–789e3. DOI: 10.1053/j.gastro.2011.12.056.
24. Churchwell M.D. et al. Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis // Nephrology Dialysis Transplantation. – 2009. – V. 24. – No 1. – P. 231–238. DOI: 10.1093/ndt/gfn467.
25. Benyoub K. et al. Amounts of bile acids and bilirubin removed during single‐pass albumin dialysis in patients with liver failure // Therapeutic apheresis and dialysis. – 2011. – V. 15. – No 5. – P. 504–506. DOI: 10.1111/j. 1744-9987.2011.00980.х.
26. Schmuck R.B. et al. Single pass albumin dialysis: a dose‐finding study to define optimal albumin concentration and dialysate flow // Artificial Organs. – 2017. – V. 41. – No 2. – P. 153–161. DOI: 10.1111/aor.12736.
27. Ho D.W.Y. et al. Selective plasma filtration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model // Gut. – 2002. – V. 50. – No 6. – P. 869–876. DOI: 10.1136/gut.50.6.869.
28. Соколов А.А. и др. Возможности селективной плазмофильтрации при заболеваниях печени // Эфферентная терапия. – 2013. – Т. 19. – № 1. – С. 103–104. [Sokolov A.A. et al. Possibilities of selective plasma filtration in liver diseases // Efferent Therapy. – 2013. – V. 19. – No 1. – P. 103–104. In Russian].
29. Фомин А.М. Оценка эффективности селективной плазмофильтрации при механической желтухе // Евразийский союз ученых. – 2016. – № 7–1 (28). – С. 43–44. [Fomin A.M. Evaluation of the effectiveness of selective plasma filtration in mechanical jaundice // Eurasian Union of Scientists. – 2016. – No 7–1 (28). – P. 43–44. In Russian].
30. Соколов А.А. и др. Сравнение селективного плазмообмена и плазморадиофильтрации системами MARS и Prometheus при лечении печеночной недостаточности // Вестник анестезиологии и реаниматологии. – 2020. – Т. 17. – № 3. – С. 39–52. [Sokolov A.A. et al. Comparison of selective plasma exchange and plasma radiofiltration by MARS and Prometheus systems in the treatment of liver failure // Bulletin of Anesthesiology and Resuscitation. – 2020. – V. 17. – No 3. – P. 39–52. In Russian]. DOI: 10.21292/2078-5658-2020-17-3-39-52.
31. Nakae H. et al. Multicenter study of plasma diafiltration in patients with acute liver failure // Therapeutic Apheresis and Dialysis. – 2010. – V. 14. – No 5. – P. 444–450. DOI: 10.1111/j.1744-9987.2010.00864.x.
32. Zhang Y. et al. Efficacy and safety of plasma diafiltration: Review of case reports and case series // Therapeutic Apheresis and Dialysis. – 2023. – V. 27. – No 1. – P. 3–11. DOI: 10.1111/1744-9987.13859.
33. Donati G. et al. Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study) // Journal of Nephrology. – 2021. – V. 34. – P. 77–88. DOI: 10.1007/s40620-020-00799-w.
34. Ocskay K. et al. Hemoadsorption in ‘liver indication’ – analysis of 109 patients’ data from the cytosorb international registry // Journal of Clinical Medicine. – 2021. – V. 10. – No 21. – P. 5182. DOI: 10.3390/jcm10215182.
35. Senf R. et al. Bilirubin-adsorption in 23 critically ill patients with liver failure // The International Journal of Artificial Organs. – 2004. – V. 27. – No 8. – P. 717–722. DOI: 10.1177/039139880402700810.
36. Adani G.L. et al. Selective bilirubin removal by plasma treatment with Plasorba BR-350 for early cholestatic graft dysfunction // Transplantation Proceedings. – Elsevier, 2007. – V. 39. – No 6. – P. 1904–1906.
37. Фомин А.М. и др. Оценка эффективности плазмосорбции (Liver Support) при печеночной недостаточности у больных с механической желтухой // Альманах клинической медицины. – 2015. – № 40. – С. 101–108. [Fomin A.M. et al. Evaluation of the effectiveness of plasmosorption (Liver Support) in hepatic insufficiency in patients with mechanical jaundice. // Almanac of Clinical Medicine. – 2015. – No 40. – P. 101–108. In Russian].
38. Huber W. et al. First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis // BMC Gastroenterology. – 2017. – V. 17. – P. 1–11. DOI: 10.1186/s12876-017-0569-x.
39. Fuhrmann V. et al. Registry on extracorporeal multiple organ support with the advanced organ support (ADVOS) system: 2-year interim analysis // Medicine. – 2021. – V. 100. – No 7. DOI: 10.1097/MD.0000000000024653.
40. Hogen R. et al. The Evolving Role of Extra-corporeal Membrane Oxygenation in Liver Transplantation // Current opinion in organ transplantation. – 2021. – V. 26. – No 3. – P. 333. DOI: 10.1097/MOT.0000000000000874.
41. Wu W.K. et al. Extracorporeal membrane oxygenation in patients with hepatopulmonary syndrome undergoing liver transplantation: a systematic review of the literature // Transplantation Reviews. – 2022. – V. 36. – No 2. – P. 100693. DOI: 10.1016/j.trre.2022.100693.
42. Reid T.D. et al. The role of extracorporeal membrane oxygenation in adult liver transplant patients: A qualitative systematic review of literature // Artificial Organs. – 2022. – V. 46. – No 4. – P. 578–596. DOI: 10.1111/aor.14120.